Jeffrey S. Flier Sells 11,136 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) Director Jeffrey S. Flier sold 11,136 shares of the business's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $33.21, for a total transaction of $369,826.56. Following the completion of the transaction, the director now directly owns 11,136 shares of the company's stock, valued at approximately $369,826.56. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Scholar Rock Trading Up 7.2%

Shares of SRRK stock traded up $2.40 on Wednesday, hitting $35.81. 1,525,718 shares of the company's stock traded hands, compared to its average volume of 1,297,592. The company's fifty day simple moving average is $31.80 and its 200 day simple moving average is $35.88. Scholar Rock Holding Corporation has a one year low of $6.76 and a one year high of $46.98. The stock has a market capitalization of $3.40 billion, a price-to-earnings ratio of -14.15 and a beta of 0.28. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.25 and a current ratio of 10.25.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the company posted ($0.59) earnings per share. Equities analysts forecast that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Lifesci Capital raised shares of Scholar Rock to a "strong-buy" rating in a report on Tuesday, June 3rd. Wedbush restated an "outperform" rating and set a $50.00 price target on shares of Scholar Rock in a research report on Wednesday, June 18th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $42.67.

Institutional Investors Weigh In On Scholar Rock

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its position in shares of Scholar Rock by 6.6% in the first quarter. Rhumbline Advisers now owns 120,752 shares of the company's stock valued at $3,882,000 after acquiring an additional 7,491 shares during the period. Strs Ohio bought a new stake in shares of Scholar Rock in the first quarter worth about $77,000. Intech Investment Management LLC increased its holdings in Scholar Rock by 60.9% during the 1st quarter. Intech Investment Management LLC now owns 56,784 shares of the company's stock valued at $1,826,000 after purchasing an additional 21,483 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Scholar Rock by 25.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company's stock valued at $5,460,000 after purchasing an additional 34,594 shares during the last quarter. Finally, Exome Asset Management LLC lifted its holdings in Scholar Rock by 8.9% in the 1st quarter. Exome Asset Management LLC now owns 84,339 shares of the company's stock worth $2,711,000 after buying an additional 6,900 shares during the period. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.